Sigilon Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SGTX research report →
Companywww.sigilon.com
Sigilon Therapeutics, Inc. , a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A.
- CEO
- Rogerio Vivaldi Coelho MBA
- IPO
- 2020
- Employees
- 62
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $56.22M
- P/E
- -16.76
- P/S
- 4.34
- P/B
- 18.60
- EV/EBITDA
- -1.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -337.35%
- Net Margin
- -335.72%
- ROE
- -74.73%
- ROIC
- -64.60%
Growth & Income
- Revenue
- $12.94M · 34.85%
- Net Income
- $-43,456,000 · 44.46%
- EPS
- $-1.34 · 95.80%
- Op Income
- $-43,666,000
- FCF YoY
- 35.18%
Performance & Tape
- 52W High
- $28.00
- 52W Low
- $3.77
- 50D MA
- $14.79
- 200D MA
- $9.81
- Beta
- 4.11
- Avg Volume
- 120.68K
Get TickerSpark's AI analysis on SGTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 11, 23 | Flagship Ventures Fund V General Partner LLC | other | 113,960 |
| Aug 11, 23 | ELI LILLY & Co | buy | 1,718,493 |
| Aug 11, 23 | Cole Douglas G. | sell | 683 |
| Aug 11, 23 | Cole Douglas G. | sell | 683 |
| Aug 11, 23 | Oesterle Stephen N. | sell | 4,273 |
| Aug 11, 23 | Oesterle Stephen N. | sell | 683 |
| Aug 11, 23 | Oesterle Stephen N. | sell | 683 |
| Aug 11, 23 | Shaff Eric D. | sell | 683 |
| Aug 11, 23 | Shaff Eric D. | sell | 683 |
| Aug 11, 23 | RUFFOLO ROBERT R | sell | 683 |
Our SGTX Coverage
We haven't published any research on SGTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SGTX Report →